A multiple myeloma (also known as Kahler disease, myelomatosis and plasma cell myeloma) is a malignant neoplasm of plasma cells which is characterised by (1,2):
- clonal proliferation of malignant plasma cells in the bone marrow microenvironment
- presence of monoclonal protein in the blood or urine
- associated organ dysfunction (1)
In the majority of cases, complete immunoglobulins are secreted together with an excess of Ig fragments. In up to one quarter of cases, Ig fragments only occur and the condition is referred to as light chain disease or Bence Jones myeloma.
Multiple myeloma is considered to evolve commonly from monoclonal gammopathy of undertermined clinical significance (MGUS) which develops to smouldering myeloma and finally to symptomatic myeloma (1).
Presentation is with anaemia, bone pain, skeletal destruction, pathologic fractures,
or Bence Jones proteinuria and increased susceptibility to infection (3).
Myeloma is the seventeenth most common cancer in the UK. In 2010, 4672 people
in the UK were diagnosed with myeloma (4)
- occurs more frequently in men and in people of African-Caribbean family
- diagnosis is often delayed because the symptoms are not specific to myeloma,
and this leads to significant early morbidity and mortality
Myeloma management is complex and challenging. Effective treatments have been
developed over the past 15 years, and although myeloma is still incurable these
treatments have led to improvements in overall survival and quality of life